|
|
Market Analysis Reports of Maytansine
|
Global Market Report of maitansine (CAS 35846-53-8)
December 2024
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis The report entitledAntibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more than 90 companies. The ...
ADC Contract Manufacturing Market (5th Edition) by Phase of Development (Phase I, Phase II and Phase III), Scale of Operation (Clinical and Commercial), Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload, Linker and Conjugation Manufacturing, and Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload (Maytansinoid, Auristatin, Camptothecin, PBD and Others), Type of Linker (SMCC, VC, Malemide, Peptide Linker and Others), Type of Antibody Origin (Humanized, Chimeric, Murine, Human and Others), Antibody Isotype (IgG1and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World), 2022-2035
The ADC contract manufacturing market is expected to reach USD 2.8 billion by 2022 anticipated to grow at a CAGR of 11.8% during the forecast period 2022-2035. Over the past two decades, antibody therapeutics have emerged as a crucial component in the ...
Competitor Analysis: Antibody-Drug Conjugates (ADC)
... two major technologies (auristatin and maytansin derivatives) have paved the way ...
|
|
|
|
